MetaVia Inc
MTVA9.190USD
-0.570-5.84%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
222.54MMarket Cap
LossP/E TTM
More Details of MetaVia Inc Company
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
MetaVia Inc Info
Ticker SymbolMTVA
Company nameMetaVia Inc
IPO dateAug 05, 2016
CEOKim (Hyung Heon)
Number of employees9
Security typeOrdinary Share
Fiscal year-endAug 05
Address545 Concord Avenue
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02138
Phone18577029600
Websitehttps://metaviatx.com/
Ticker SymbolMTVA
IPO dateAug 05, 2016
CEOKim (Hyung Heon)
Company Executives of MetaVia Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Hyung Heon Kim
Mr. Hyung Heon Kim
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.25K
+20.36%
Mr. Andrew Ian Koven
Mr. Andrew Ian Koven
Independent Chairman of the Board
Independent Chairman of the Board
3.91K
+339.86%
Mr. Jason L. Groves, Esq., J.D.
Mr. Jason L. Groves, Esq., J.D.
Independent Director
Independent Director
3.91K
+339.86%
Mr. Michael Salsbury
Mr. Michael Salsbury
Independent Director
Independent Director
3.91K
+339.86%
Mr. Mark A. Glickman
Mr. Mark A. Glickman
Independent Director
Independent Director
3.37K
+850.14%
Mr. Marshall H. Woodworth
Mr. Marshall H. Woodworth
Chief Financial Officer
Chief Financial Officer
603.00
-68.16%
Dr. James Patrick (Jim) Tursi, M.D.
Dr. James Patrick (Jim) Tursi, M.D.
Independent Director
Independent Director
--
--
Mr. D. Gordon Strickland
Mr. D. Gordon Strickland
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Hyung Heon Kim
Mr. Hyung Heon Kim
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.25K
+20.36%
Mr. Andrew Ian Koven
Mr. Andrew Ian Koven
Independent Chairman of the Board
Independent Chairman of the Board
3.91K
+339.86%
Mr. Jason L. Groves, Esq., J.D.
Mr. Jason L. Groves, Esq., J.D.
Independent Director
Independent Director
3.91K
+339.86%
Mr. Michael Salsbury
Mr. Michael Salsbury
Independent Director
Independent Director
3.91K
+339.86%
Mr. Mark A. Glickman
Mr. Mark A. Glickman
Independent Director
Independent Director
3.37K
+850.14%
Mr. Marshall H. Woodworth
Mr. Marshall H. Woodworth
Chief Financial Officer
Chief Financial Officer
603.00
-68.16%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Dong-A ST Co., Ltd.
61.23%
The Vanguard Group, Inc.
0.63%
Geode Capital Management, L.L.C.
0.29%
SG Americas Securities, L.L.C.
0.25%
Kim (Hyung Heon)
0.24%
Other
37.36%
Shareholders
Shareholders
Proportion
Dong-A ST Co., Ltd.
61.23%
The Vanguard Group, Inc.
0.63%
Geode Capital Management, L.L.C.
0.29%
SG Americas Securities, L.L.C.
0.25%
Kim (Hyung Heon)
0.24%
Other
37.36%
Shareholder Types
Shareholders
Proportion
Corporation
61.23%
Individual Investor
1.28%
Investment Advisor
0.66%
Research Firm
0.60%
Investment Advisor/Hedge Fund
0.41%
Hedge Fund
0.19%
Other
35.62%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
31
366.19K
1.51%
-533.63K
2025Q2
39
15.87M
65.59%
+4.69M
2025Q1
40
6.18M
66.88%
-362.61K
2024Q4
48
6.53M
78.71%
-206.27K
2024Q3
44
6.72M
80.64%
+31.88K
2024Q2
51
6.49M
81.55%
+3.23M
2024Q1
54
3.12M
64.62%
+1.15M
2023Q4
53
1.92M
74.31%
+1.65M
2023Q3
54
1.93M
74.71%
+1.67M
2023Q2
60
1.75M
73.99%
+1.49M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Dong-A ST Co., Ltd.
14.83M
61.27%
+4.83M
+48.34%
Jun 09, 2025
The Vanguard Group, Inc.
63.58K
0.26%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
35.87K
0.15%
-4.51K
-11.17%
Jun 30, 2025
SG Americas Securities, L.L.C.
41.88K
0.17%
+880.00
+2.15%
Jun 30, 2025
Kim (Hyung Heon)
57.75K
0.24%
+9.77K
+20.35%
Jun 09, 2025
Koven (Andrew Ian)
42.97K
0.18%
+33.20K
+339.90%
Jun 30, 2025
Groves (Jason L)
42.97K
0.18%
+33.20K
+339.90%
Jun 30, 2025
Strickland (D Gordon)
42.96K
0.18%
+33.20K
+339.93%
Jun 30, 2025
Salsbury (Michael)
42.97K
0.18%
+33.20K
+339.90%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 08, 2023
Merger
8→1
Aug 08, 2023
Merger
8→1
Aug 08, 2023
Merger
8→1
Aug 08, 2023
Merger
8→1
Sep 12, 2022
Merger
30→1
Sep 12, 2022
Merger
30→1
Date
Type
Ratio
Aug 08, 2023
Merger
8→1
Aug 08, 2023
Merger
8→1
Aug 08, 2023
Merger
8→1
Aug 08, 2023
Merger
8→1
Sep 12, 2022
Merger
30→1
Sep 12, 2022
Merger
30→1
Sep 12, 2022
Merger
30→1
Sep 12, 2022
Merger
30→1
FAQs
Who are the top five shareholders of MetaVia Inc?
The top five shareholders of MetaVia Inc are:
Dong-A ST Co., Ltd. holds 14.83M shares, accounting for 61.27% of the total shares.
The Vanguard Group, Inc. holds 63.58K shares, accounting for 0.26% of the total shares.
Geode Capital Management, L.L.C. holds 35.87K shares, accounting for 0.15% of the total shares.
SG Americas Securities, L.L.C. holds 41.88K shares, accounting for 0.17% of the total shares.
Kim (Hyung Heon) holds 57.75K shares, accounting for 0.24% of the total shares.
Dong-A ST Co., Ltd. holds 14.83M shares, accounting for 61.27% of the total shares.
The Vanguard Group, Inc. holds 63.58K shares, accounting for 0.26% of the total shares.
Geode Capital Management, L.L.C. holds 35.87K shares, accounting for 0.15% of the total shares.
SG Americas Securities, L.L.C. holds 41.88K shares, accounting for 0.17% of the total shares.
Kim (Hyung Heon) holds 57.75K shares, accounting for 0.24% of the total shares.
What are the top three shareholder types of MetaVia Inc?
The top three shareholder types of MetaVia Inc are:
Dong-A ST Co., Ltd.
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
Dong-A ST Co., Ltd.
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
How many institutions hold shares of MetaVia Inc (MTVA)?
As of 2025Q3, 31 institutions hold shares of MetaVia Inc, with a combined market value of approximately 366.19K, accounting for 1.51% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -64.08%.
What is the biggest source of revenue for MetaVia Inc?
In --, the -- business generated the highest revenue for MetaVia Inc, amounting to -- and accounting for --% of total revenue.
